Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study.
Potential adverse effects of COVID19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study.
复制标题
DOI:
10.1016/j.dsx.2021.102207
复制
发表时间:
2021-09
期刊:
影响因子:
--
通讯作者:
Merza MA
中科院分区:
文献类型:
--
作者:
Almufty HB;Mohammed SA;Abdullah AM;Merza MA
the objectives of this study are to reveal the potential side effects after taking the covid19 vaccines, associated risk factors with severe side effects, and to compare the three COVID-19 vaccines available in Iraq (Sinopharm, AstraZeneca-Oxford and Pfizer- BioNTech). a randomized cross-sectional study was conducted in April 2021. A standardized questionnaire platform was utilized to collect information about the Iraqi population. 1012 were enrolled in the study, 60.2% were male and 39.8% were female. 84% were symptomatic post vaccination. Young aged participants, females, participants with history of COVID19 infection, those with comorbid diseases and AstraZeneca vaccine receivers were statistically significant risk factors for having adverse reactions post vaccination, P value (0.03, 0.028, 0.007, 0.019 and 0.0001) respectively. Regarding severity of symptoms, most symptoms were mild and moderate. Residency in Kurdistan Region of Iraq and AstraZeneca vaccine were the statistically significant risk factors for getting severe symptoms P value < 0.0001 of both. Females were an associated risk factor for D-dimer elevation P value = 0.05. fatigue, injection site reactions, fever, myalgia, headache and chills were the most reported side effects. Most symptoms were mild to moderate in term of severity.
登录
查看更多内容
DOI:
10.1016/s0140-6736(20)32661-1
发表时间:
2021-01-09
期刊:
Lancet (London, England)
影响因子:
--
作者:
Voysey M;Clemens SAC;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Collins AM;Colin-Jones R;Cutland CL;Darton TC;Dheda K;Duncan CJA;Emary KRW;Ewer KJ;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Goodman AL;Green CM;Green CA;Heath PT;Hill C;Hill H;Hirsch I;Hodgson SHC;Izu A;Jackson S;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Lawrie AM;Lelliott A;Libri V;Lillie PJ;Mallory R;Mendes AVA;Milan EP;Minassian AM;McGregor A;Morrison H;Mujadidi YF;Nana A;O'Reilly PJ;Padayachee SD;Pittella A;Plested E;Pollock KM;Ramasamy MN;Rhead S;Schwarzbold AV;Singh N;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Tarrant R;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;Watson MEE;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者:
Oxford COVID Vaccine Trial Group
DOI:
10.3390/life11030249
发表时间:
2021-03-17
期刊:
Life (Basel, Switzerland)
影响因子:
--
作者:
Mathioudakis AG;Ghrew M;Ustianowski A;Ahmad S;Borrow R;Papavasileiou LP;Petrakis D;Bakerly ND
通讯作者:
Bakerly ND
DOI:
10.1056/nejmoa2104840
发表时间:
2021-06-03
期刊:
The New England journal of medicine
影响因子:
--
作者:
Greinacher A;Thiele T;Warkentin TE;Weisser K;Kyrle PA;Eichinger S
通讯作者:
Eichinger S
影响因子:
10.4
作者:
Nazy, Ishac;Sachs, Ulrich J.;Bakchoul, Tamam
通讯作者:
Bakchoul, Tamam
影响因子:
7.8
作者:
Kounis NG;Koniari I;de Gregorio C;Velissaris D;Petalas K;Brinia A;Assimakopoulos SF;Gogos C;Kouni SN;Kounis GN;Calogiuri G;Hung MY
通讯作者:
Hung MY